Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility. For more information, visit: http://www.cancertypeid.com
Author: admin
Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer Index (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer Research and Royal Marsden Hospital, London, UK, discusses the results of the double-blind, phase 3 PALOMA3 trial of fulvestrant with or without the novel cyclin-dependent kinase 4/6 inhibitor, palbociclib, in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who progressed on prior endocrine therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the recent progress in understanding clinically relevant genomic alterations in kidney cancer. Genomic profiling of collecting duct carcinomas, a rare kidney cancer subtype, revealed a high frequency of NF2 genomic alterations, which may represent opportunities for the application of targeted therapies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the recent development of molecularly targeted therapies in the management of haematological malignancies. Emerging targeted agents include monoclonal antibody (mAb) targeting Signaling Lymphocytic Activation Molecule F7 (SLAMF7), elotuzumab, for multiple myeloma; anti-CD38 mAb, daratumumab, for multiple myeloma; anti-CD20 mAb, obinutuzumab, for chronic lymphocytic leukaemia (CLL); and ibrutinib plus bendamustine for CLL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting on new treatments for patients with multiple myeloma. Topics of interest include chimeric antigen receptor (CAR) T-cell therapy, the anti-CS1 humanised monoclonal antibody, elotuzumab, lenalidomide maintenance therapy, first-line treatment of newly diagnosed multiple myeloma using lenalidomide plus dexamethasone, and the histone deacetylase (HDAC) inhibitor, panobinostat. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune response from STRIDE, a randomised, phase 2, open-label trial of sipuleucel-T with concurrent versus sequential enzalutamide administration in patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, describes ASCO’s initiatives for the upcoming year. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer Index (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy. For more information, visit: http://www.cancertypeid.com
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, reviews the results of the phase 3 CheckMate 067 trial of nivolumab in treatment-naive patients with advanced melanoma, and the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Jacqueline Barrientos, MD, summarises recent progress in the treatment of chronic lymphocytic leukaemia at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. He highlights trials on combined BRAF and MEK inhibition versus BRAF inhibition alone, and immunotherapy drug combinations. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naive patients with advanced melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses the results of the randomised, double-blinded, phase 3 COMBI-d trial, which compared the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Andrew B. Lassman, MD, of Columbia University Medical Center, New York, NY, discusses the results of the randomised phase 3 NCCTG N0574 (Alliance) trial of whole brain radiation therapy in addition to stereotactic radiosurgery in patients with 1 to 3 brain metastases. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, provides an overview of the current unmet needs in the treatment of metastatic kidney cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium, discusses the results of a randomised, open-label, multicentre, phase 3 trial of the microtubule dynamics inhibitor, eribulin, versus dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Michael J. Mauro, MD, provides a summary of the SIMPLICITY trial. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Stuart L. Goldberg, MD provides CML meeting highlights live from the 2015 ASCO Annual Meeting that significantly impact practice. For additional meeting highlights from other congresses, http://managingcml.com/con-ed-cml/annual-meeting-highlights-cml For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter discusses the efficacy and safety considerations in using ponatinib. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter discusses the most common reasons for treatment failur For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter discusses using second-generation TKIs as a first-line approach. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients. For more information, tools, resources and CE activities please http://managingcml.com/ Managing CML is an educational online community for health care professionals who provide care to patients with chronic myelogenous leukemia, or CML. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this hematologic malignancy in your clinical practice.
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lenvatinib is an oral tyrosine kinase inhibitor of the VEGFR13, FGFR14, PDGFR?, RET, and KIT signaling networks. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results of the multi-arm phase 1 TATTON trial, which evaluated the mutant-selective EGFR tyrosine kinase inhibitor, AZD9291, combined with MEDI4736 (anti-PD-L1 monoclonal antibody), savolitinib (MET inhibitor) or selumetinib (MEK1/2 inhibitor) in patients with EGFR-mutant lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Is there a role for second-line therapy in advanced pancreatic cancer? For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Koushik Das discusses the type of patients that would benefit from pancreatic cancer screening. For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Koushik Das discusses screening tests and predictive biomarkers for pancreatic cancer. For more information, tools, resources and CE activities please http://partnersinpancreaticcancer.com/ Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Jill Lacy discusses radiotherapy in the treatment of pancreatic cancer, how its role is evolving in specific settings, and when and how to use radiotherapy in pancreatic cancer. For more information, tools, resources and CE activities please partnersinpancreaticcancer.com Partners in Pancreatic Cancer is an educational online community for health care professionals who provide care to patients with pancreatic cancer. Our mission is to provide ongoing evidence-based scientific data and the most up-to-date information, tools, and resources for treating this devastating disease in your clinical practice.
Dr. Jill Lacy discusses the development of immune therapies for pancreas cancer, the progress that is being made, and provides an update on CRS-207 and GVAX.
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 multicentre, randomised, open-label MCL-002 (SPRINT) trial of lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, versus investigators choice (chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab) in patients with relapsed/refractory mantle cell lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses ongoing clinical studies by the German CLL Study Group (GCLLSG) that are investigating new therapies for patients with chronic lymphocytic leukaemia (CLL), including obinutuzumab in combination with chlorambucil; a watch-and-wait strategy; and a four-arm study comparing standard chemotherapy versus non-chemotherapy-containing regimens. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the first results from the phase 3 HELIOS trial, which evaluated the first-in-class, oral covalent Bruton’s tyrosine kinase inhibitor, ibrutinib, in combination with bendamustine and rituximab (BR) versus BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the ClÃnica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label, randomised phase 3 ENDEAVOR study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the results of the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study. EXELS study is an observational phase 4 study that compared safety, pregnancy outcomes, and efficacy (measured by incidence of thrombohaemorrhagic events and platelet reduction) of anagrelide compared with other cytoreductive therapies in high-risk patients with essential thrombocythemia (ET). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Breast Cancer Index (BCI) is a molecular, gene expression-based test uniquely positioned to identify patients best suited for extended endocrine treatment. It is the only validated, commercially available test that provides prognostic risk of late recurrence (5-10 years post-diagnosis), as well as prediction of extended endocrine therapy benefit. The breakthrough test helps oncologists and patients navigate the difficult trade-off between wanting to take steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to extended endocrine therapy. Breast Cancer Index (BCI) was granted Medicare coverage in October 2014. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com…
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies. For more information, visit: http://www.cancertypeid.com
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses the trial design and results of the phase 3 PERSIST-1 trial of pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses follow-up data of the RESPONSE trial, which is a multicentre, open-label phase 3 study evaluating the efficacy and safety of ruxolitinib compared with best available therapy in patients with polycythemia vera resistant to or intolerant of hydroxyurea. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, MarÃa-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the results of the phase 2 MMY2002 trial of the anti-CD38 monoclonal antibody, daratumumab, in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. Daratumumab is a novel therapeutic human CD38 monoclonal antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses the results of the phase 3 PERSIST-1 trial of the selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3, pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Patrick I. Borgen, M.D, of the Brooklyn Breast Cancer Center talks about reducing opioids in breast cancer surgery using Bupivacaine
Charles L. Loprinzi, MD, of the Mayo Clinic discusses the management of Hot Flashes using SSRI, Gabapentin, Venlafaxine in patients with breast cancer
Charles L. Loprinzi, MD, of the Mayo Clinic reviews how Olanzapine Decreases Nausea and Vomiting in Patients With Esophageal, Head and Neck Cancer
Charles L. Loprinzi, MD, of the Mayo Clinic talks about scrambler therapy for the treatment of chemotherapy- induced peripheral neuropathy
Hope S. Rugo, MD of the UCSF Medical Center talks about the I-SPY 2 Trial and MK-2206 which shows benefit for breast cancer patients